PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
Animals
Antibodies
/ immunology
Antineoplastic Combined Chemotherapy Protocols
/ immunology
B7-H1 Antigen
/ antagonists & inhibitors
Cell Line, Tumor
Colorectal Neoplasms
/ drug therapy
DNA
/ genetics
Drug Synergism
Female
Genes, BRCA1
Genes, BRCA2
Humans
Membrane Proteins
/ immunology
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Knockout
Mice, Nude
Ovarian Neoplasms
/ drug therapy
Poly(ADP-ribose) Polymerase Inhibitors
/ immunology
Signal Transduction
/ drug effects
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
15 01 2019
15 01 2019
Historique:
received:
03
04
2018
revised:
13
08
2018
accepted:
20
11
2018
pubmed:
30
11
2018
medline:
2
11
2019
entrez:
29
11
2018
Statut:
ppublish
Résumé
PARP inhibitors (PARPi) have shown remarkable therapeutic efficacy against
Identifiants
pubmed: 30482774
pii: 0008-5472.CAN-18-1003
doi: 10.1158/0008-5472.CAN-18-1003
pmc: PMC6588002
mid: NIHMS1514951
doi:
Substances chimiques
Antibodies
0
B7-H1 Antigen
0
Membrane Proteins
0
Poly(ADP-ribose) Polymerase Inhibitors
0
STING1 protein, human
0
Sting1 protein, mouse
0
DNA
9007-49-2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
311-319Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA217685
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA181663
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA217842
Pays : United States
Informations de copyright
©2018 American Association for Cancer Research.
Références
J Natl Cancer Inst. 2016 Oct 5;109(1):
pubmed: 27707838
J Clin Invest. 2016 Jul 1;126(7):2404-11
pubmed: 27367184
N Engl J Med. 2012 Apr 12;366(15):1382-92
pubmed: 22452356
Immunol Rev. 2014 Nov;262(1):167-78
pubmed: 25319334
BMC Biol. 2016 Aug 18;14:69
pubmed: 27538435
Nat Med. 2008 Jan;14(1):28-36
pubmed: 18157142
EMBO J. 2010 Sep 1;29(17):2864-74
pubmed: 20647996
J Immunol. 2012 Dec 15;189(12):5602-11
pubmed: 23152559
Neuro Oncol. 2017 Jun 1;19(6):796-807
pubmed: 28115578
Cancer Res. 2012 Aug 1;72(15):3735-43
pubmed: 22593190
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
N Engl J Med. 2009 Jul 9;361(2):123-34
pubmed: 19553641
Cell Host Microbe. 2016 Feb 10;19(2):150-8
pubmed: 26867174
Nature. 2013 Jun 20;498(7454):380-4
pubmed: 23722158
Gut. 2017 Jan;66(1):124-136
pubmed: 27402485
Front Immunol. 2017 Feb 06;8:86
pubmed: 28220123
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
Lancet Oncol. 2011 Sep;12(9):852-61
pubmed: 21862407
Cancer Treat Rev. 2018 Feb;63:40-47
pubmed: 29207310
Nature. 2017 Aug 24;548(7668):466-470
pubmed: 28759889
Nature. 2005 Apr 14;434(7035):913-7
pubmed: 15829966
Mol Oncol. 2013 Jun;7(3):567-79
pubmed: 23415752
Nat Rev Mol Cell Biol. 2017 Oct;18(10):610-621
pubmed: 28676700